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INTRODUCTION 71
Human herpesvirus 6B (HHV-6B) is a double-stranded DNA virus that infects the majority of 72 people during infancy and establishes latency in a diverse array of cell types. 1 73 Immunosuppression due to allogeneic hematopoietic cell transplantation (HCT) results in 74 frequent viral reactivation with detection of HHV-6B DNA viremia in approximately 40-60% of 75 patients. HHV-6B reactivation is the most frequent cause of encephalitis in HCT recipients, 76 affecting 1-10% of patients, 2 and HHV-6B is associated with a variety of disease processes in 77 both immunocompromised and immunocompetent individuals. 1 Quantitative polymerase chain 78 reaction (qPCR) assays to detect HHV-6B genomic DNA in biologic samples are limited by the 79 detection of latent virus and low specificity for end-organ disease. [3] [4] [5] [6] [7] This is especially 80 problematic in patients with inherited chromosomally integrated HHV-6B (iciHHV-6B), who have 81 a high burden of cell-associated HHV-6 DNA due to integration of the viral genome in every 82 nucleated cell. 8, 9 These limitations in identification of HHV-6B reactivation and associated 83 pathogenicity confound research and treatment efforts for HHV-6B. 10 84
Molecular detection of HHV-6B gene transcripts using reverse transcription real-time 85 qPCR (RT-qPCR) has potential to improve the specificity of diagnostic studies for HHV-6B 86 reactivation. This method of amplifying messenger (m)RNA from infected cells may provide a 87 better approach to distinguish active from latent infections. A few studies have reported the 88 development and application of assays to detect HHV-6 mRNA transcripts including open 89 reading frames (ORFs) U12, U16/17, U60/66, U79/U80, U89/90, and U100. 11-17 However, these 90 studies have been limited by reliance on in vitro data for transcript selection, use of selected 91 mRNA targets based on spliced gene products, and suboptimal RNA preservation due to 92 sample collection methods. High throughput qualitative profiling of transcript changes using 93 microarrays have been used to identify HHV-6B gene expression with in vitro cell lines in one 94 study, 18 but these methods may also produce biased results through the use of predefined unbiased next generation RNA sequencing (RNA-seq) in tissue samples from two patients with 97 diffuse large B-cell lymphoma (DLBCL). 19 98
We sought to characterize in vivo HHV-6B gene expression using high-throughput RNA-99 seq on polyA-selected RNA isolated from whole blood samples in HCT recipients with HHV-6B 100 reactivation. To facilitate identification of highly expressed mRNA transcripts in biologic 101 specimens to guide development of diagnostic assays, we compared HHV-6B gene expression 102 patterns in whole blood to data from a study using tumor tissue samples and to cell cultures with 103 lytic, latent, and iciHHV-6B. We also assessed whether we could identify distinct host gene 104 transcription and cytokine profiles among HCT recipients with and without HHV-6B DNA 105 detection in plasma samples. 106
107

METHODS AND MATERIALS 108
Patients 109
We identified a cohort of patients who had whole blood collected in PAXgene Blood RNA 110 tubes (PAXgene tubes; QIAGEN, Germantown, MD) within the first six weeks of autologous or 111 allogeneic HCT as part of an unrelated study. We then identified plasma samples from these 112 subjects that were collected on the day of PAXgene tube collection and temporally proximal, 113 both before and after. We tested these samples for HHV-6B DNA using qPCR. Patients who 114 had plasma HHV-6B DNA detected within 7 days of PAXgene tube collection were selected for 115 this study and were categorized as cases; one patient was included with 11 days between 116 sample collection and HHV-6B detection ( Table 1) . Patients without HHV-6B detection in 117 plasma samples within 7 days of PAXgene tube acquisition were used as controls and matched 118 in a 1 to 1 ratio to cases based on the day post-HCT of PAXgene tube collection, age, race, sex, 119 type of HCT (autologous versus allogeneic), donor relation, human leukocyte antigen (HLA) 120 matching, neutrophil engraftment status, and acute graft-versus-host disease (aGVHD) status
We also used data from two patients with DLBCL from a published study in which RNA-123 seq on tumor tissue samples demonstrated a broad profile of HHV-6B transcripts consistent 124 with lytic transcription. 19 125 126
Samples 127
PAXgene tubes were filled with 2.5 ml of whole blood obtained directly from HCT 128 recipients, and samples were stored according to the manufacturer's instructions. Plasma 129 samples were leftover clinical specimens used for cytomegalovirus testing. For in vitro 130 comparisons, we obtained a cell culture of HHV-6B Z29 infected SupT1 CD4+ T cells (provided 131 by the HHV-6 Foundation). Cells were harvested 48 hours after infection. We also obtained two 132 beta lymphoblastoid cell lines (B-LCLs) derived from pre-HCT PBMCs from one subject with 133 low-level virus detection due to acquired, latent HHV-6B infection and one subject with iciHHV-134 6B identified in a prior study. 20 The presence or absence of iciHHV-6B in each of the B-LCLs 135 was confirmed by droplet digital PCR as previously described. 9 136 137
HHV-6B DNA testing 138
We tested plasma samples for HHV-6B DNA using high-throughput real-time qPCR that 139 detects 1 copy of HHV-6 DNA per reaction (25 copies/ml) and distinguishes between species A 140 and B as previously described. 21 141
142
RNA extraction 143
We isolated and extracted total RNA from PAXgene tubes according to the 144 manufacturer's instructions using the MagMAX Blood RNA kit (Ambion, Foster City, CA). RNA 145 quality was determined by electropherogram (showing 28S, 18S, and 5S bands) and RNA 146 integrity number using an Agilent 2200 Bioanalyzer (Agilent Technologies, Santa Clara, CA). 147
Total RNA concentration was obtained from an absorbance ratio at 260 and 280 nm using a NanoDrop ND-2000 spectrometry instrument (NanoDrop Technologies, Wilmingtion, DE). Since 149 whole blood RNA consists mostly of globin mRNA, we performed globin depletion using the 150 GLOBINclear kit (Ambion, Foster City, CA) to maximize detection of less abundant mRNA and 151 further purified and concentrated RNA on appropriate columns before RNA library preparation. 152
153
RNA sequencing 154
We performed polyA-RNA (coding mRNA) selection to minimize DNA contamination. 
Patients 216
We identified seven subjects (cases 1-7) with whole blood PAXgene tubes obtained 217 post-HCT who had concurrent HHV-6B DNA detection in plasma by qPCR with a median of 4 218 days (range, 0-11) between plasma detection and PAXgene tube collection. HHV-6B was 219 detected in plasma samples prior to, on the day of, and after the day PAXgene tube collection in 220 2, 1, and 3 cases, respectively; HHV-6B was detected prior to and after the day of PAXgene 221 tube collection in 1 case ( Table 1) . Matched controls who had a PAXgene tube collected and 222 did not have HHV-6B DNA plasma detection within 7 days of the PAXgene tube collection were 223 identified for cases 1-5. Demographics and clinical characteristics of the cohort are presented in 224 Table 2 . None of the subjects developed HHV-6-associated end-organ disease. In addition, we obtained RNA-seq data sets from two patients with DLBCL who had HHV-6B gene expression 226 demonstrated in tumor tissue samples. 19 227 228 mRNA isolation from PAXgene tubes 229
We isolated sufficient mRNA to allow for high throughput sequencing for five of seven 230 cases and three of five controls ( Table 3) . There was substantial variability in complete blood 231 counts for each subject at the time of PAXgene tube collection due to sample acquisition within 232 the first few weeks after HCT ( Table 3 ). The lowest yields of total RNA were observed for 233 individuals with the lowest absolute white blood cell (WBC) counts. The two cases and two 234 controls with insufficient RNA recovery had PAXgene tubes obtained the earliest after HCT 235 (within 14 days) and prior to neutrophil engraftment. 236 237
Comparison of the HHV-6B transcriptome in whole blood, DLBCL tumor tissue, and 238
SupT1 CD4+ T cells with lytic HHV-6B Z29 infection 239
We sought to characterize and compare the relative abundance of HHV-6B transcripts 240 between whole blood from post-HCT patients with and without HHV-6B plasma viremia, tissue 241 samples from patients with DLBCL, and a SupT1 CD4+ T cell culture with lytic HHV-6B Z29 242 infection. In post-HCT whole blood samples from the five cases and three controls with sufficient 243 RNA isolation, transcriptome analysis using RNA-seq identified HHV-6B gene expression in four 244 of five cases and zero of three controls (Table 3) . Overall, whole blood samples had low HHV-245 6B gene counts with a range of 0.03 to 19 VPMM per sample ( Table 3 ). In comparison, tumor 246 tissue samples from two patients with DLBCL had 21 and 94 HHV-6B VPMM ( Table 3) . The in 247
vitro SupT1 CD4+ T cell culture with lytic HHV-6B Z29 infection had the highest HHV-6B gene 248 count with 7,040 VPPM ( Table 3) . 249
In post-HCT whole blood, a broad array of HHV-6B genes was detected from cases 2 250 and 7 including immediate early, early, and late genes (Tables S1, S2; Figure 1 ). In cases 1 251 and 3, we only detected HHV-6B reads mapping to ORF U38. Tumor tissue samples from the 252 two patients with DLBCL had an overall increased diversity of HHV-6B gene expression to most We compared the top ten HHV-6B transcripts with the highest normalized number of 265 reads from each sample type (Table 4 ). This demonstrated that reads mapping to HHV-6B 266 transcripts associated with expression of ORF U38, a viral polymerase gene, were the only 267 transcripts detected at relatively high levels in all the RNA-seq data sets. Overall, five of the top 268 ten HHV-6B genes (ORFs U95, U79, U41, U38, and U14) were shared between all three 269 sample types, demonstrating high concordance between in vitro and in vivo HHV-6B gene 270 transcripts in the setting of lytic infection. Reads mapping to late gene transcripts (ORFs U57, 271 U54, U41, and U38) were more prevalent in the DLBCL tissue samples than whole blood 272 samples (ORF U38 only). 273
HHV-6B transcriptome in B-LCLs with latent and iciHHV-6B 276
We did not detect reads aligning to any specific viral transcripts in data sets from a B-277 LCL sample with latent HHV-6B infection from post-natal infection or a B-LCL sample with 278 inherited chromosomally integrated HHV-6B. Although we did identify several reads containing 279 the TAACCC nucleotide sequence, we could not determine the origin of this RNA transcript 280
given that this telomeric repeat sequence is found in both HHV-6B and human genomes. 281 282
Development and validation of a RT-qPCR assay for ORF U38 283
We selected ORF U38 as the best candidate for a diagnostic target to identify lytic HHV-284 6B replication in biologic samples based on our findings that ORF U38 was highly expressed in 285 all sample types and the only transcript detected in all samples with HHV-6B gene expression. 286
To confirm the detection of reads mapping to ORF U38, we developed a specific RT-qPCR 287 assay to detect this mRNA transcript. Using this newly developed assay, we tested mRNA 288 extracted from whole blood in four of the post-HCT cases with HHV-6B plasma detection who 289 had a second available PAXgene tube. We detected the ORF U38 transcript in all four cases 290 (Table 5) . Additionally, the high sensitivity of this assay was demonstrated by the detection of 291 U38 mRNA from one subject in which RNA-seq did not identify any HHV-6B gene transcripts 292 (case 4), as well as another case in which there was an insufficient amount of isolated RNA to 293 perform RNA-seq (case 5). The number of ORF U38 copies detected by RT-qPCR correlated 294 with the number of reads mapping to ORF U38 by RNA-seq (r 2 = 1.0; p = 0.08), but this did not 295 reach statistical significance, likely due to the small sample size. 296
Because the HHV-6B ORF U38 is not a spliced gene product, there is a possibility of 297 amplification of contaminating HHV-6B genomic DNA. Although we performed a DNase 298 treatment to mitigate contaminating DNA, we performed an RT-qPCR reaction excluding 299 reverse transcriptase to assess for genomic HHV-6B DNA contamination. There was evidence 302
Host cellular gene transcriptome and cytokines in whole blood samples from post-HCT 303 cases and controls 304
We performed a differential gene expression analysis of host cellular gene expression 305 profiles in whole blood comparing normalized read counts from RNA-seq data sets between 306 post-HCT cases and controls to determine whether we could distinguish between individuals 307 with and without HHV-6B reactivation. We did not observe statistically significant differences in 308 cellular gene expression in any of the paired samples (data not shown). Using a commercially 309 available Luminex based assay, we also tested plasma samples obtained pre-and post-310
PAXgene tube whole blood collection for 14 immuno-inflammatory cytokines from cases and 311 controls (see Supplement). All the cytokines tested in plasma were at or below the limit of 312 detection and precluded analysis of differential cytokine expression between individuals with 313 and without HHV-6B reactivation (data not shown). 314 315
Structure of select HHV-6B transcripts from whole blood and DLBCL tumor tissue 316 samples during HHV-6B replication 317
We recently reported differential splicing patterns of several HHV-6B transcripts in cell 318 lines following in vitro infection, sometimes involving unpredicted splicing sites compared to the 319 reference genome annotation. 26 These findings could affect the performance of diagnostic RT-320 qPCR assays targeting these transcripts. In the current study, we characterized select HHV-6B 321 spliceoforms that were detected at relatively high levels (ORFs U79, U95, and U100) in post-322
HCT whole blood and DLBCL tumor tissue samples. Our analysis of the mapped reads revealed 323 that all detected splice sites contained the canonical dinucleotides GT and AG for donor and 324 acceptor sites, respectively (Table S3) . 325
For the HHV-6B U79 transcript, four different mRNA spliceoforms have been previously 326 described and sequenced. 27 An additional U79 mRNA isoform was recently identified in T cell lines following experimental infection with HHV-6B, and its translation into protein was 328 confirmed using mass spectrometry. 26 In our current study, RNA-seq data from whole blood 329 samples demonstrated an additional novel U79 splice variant corresponding to an open reading 330 frame including exon I, exon II, intron II, and a partial sequence from exon III (Figure S1 ). Using 331 proteomic data from a previously published study, 26 we discovered a HHV-6B peptide sequence 332 corresponding to the sequence encoded by intron II of the U79 mRNA (peptide sequence 333 VYAQVGGVLGSPKR). This U79 mRNA isoform was also detected in one of the 3 U79 mRNA 334 isoforms from the DLBCL tumor tissue. 335
The structure of the HHV-6B U95 transcript has been previously reported. 27 Our RNA-336 seq data from whole blood samples confirmed that the transcription start site is located 337 upstream of the initiating ATG sequence and that the transcript consists of two exons on both 338 sides of ORF U94. 339
For the HHV-6B U100 transcript, a previous study showed the viral transcripts encode 340 for two glycoproteins designated gQ1 and gQ2, both of which are expressed on the viral 341 envelope in the form of a tetrameric complex with glycoproteins gH and gL. 27 Our RNA-seq data 342 from whole blood samples revealed reads mapping to either gQ1 or gQ2. In contrast, data from 343 the DLBCL tumor tissue reads mapped to both gQ1 and gQ2 simultaneously. These 344 observations suggest that each glycoprotein expression could be independently regulated, 345 which is further supported by the existence of a polyA sequence at the end of the gQ1 open 346 reading frame. Additionally, our analysis of reads mapping to the gQ2 transcript showed two 347 possible splice sites, and the mature transcript corresponding to the alternative gQ2 splice is 348 predicted to code for a shorter protein (68 amino acids versus 182 amino acids, Figure S2) . 349
Further experiments are required to establish the biological relevance of this gQ2 protein 350 isoform. 351
DISCUSSION 354
We used RNA-seq to characterize the in vivo HHV-6B transcriptome in whole blood 355 samples collected from allogeneic HCT recipients and compared this to the HHV-6B 356 transcriptome in DLBCL tumor tissue and to HHV-6B infected SupT1 CD4+ cells in culture. We 357 observed concordance between the HHV-6B transcriptome observed in the in vivo and in vitro 358 samples, although there was substantial variability in the breadth and quantity of gene 359 expression across sample types. The HHV-6B viral polymerase gene U38 was the only 360 transcript detected in all RNA-seq data sets and was one of the top ten most highly expressed 361 genes. Using a novel RT-qPCR assay, we detected the HHV-6B U38 gene in all tested whole 362 blood samples from patients with concurrent HHV-6B viremia, suggesting that this is a sensitive 363 assay for HHV-6B replication. The splicing pattern for the HHV-6B U79 and U100 genes in 364 whole blood samples demonstrated discrepancies with the predicted splice sites as annotated in 365 the HHV-6B reference genome, and caution is required in designing PCR assays for these 366
targets. 367
Quantitative PCR to detect HHV-6B genomic DNA is the standard clinical approach for 368 diagnostic testing. However, this has important limitations in specificity given that most humans 369 are infected with HHV-6B early in life, HHV-6B remains latent in a diverse array of cell types, 370 and about 1% of the population has iciHHV-6 (species A or B) with a high burden of cell-371 associated HHV-6 DNA. 10 Thus, it may be difficult to distinguish between latent and actively 372 replicating virus when HHV-6B DNA is detected by qPCR in cellular samples. For a related 373 herpesvirus, cytomegalovirus (CMV), the use of RT-qPCR to identify CMV transcripts in 374 bronchoalveolar lavage fluid of immunocompromised patients demonstrated significantly greater 375 specificity for CMV pneumonia than standard qPCR, which has poor specificity due to the 376 detection of latent virus and viral shedding. 28 Development of RT-qPCR assays to detect HHV-377 6B mRNA may provide a more accurate method for identifying active infection, and studies specificity for viral replication in vivo. 11, 16, 17 However, HHV-6B transcript targets that have been 380 studied to date were selected based on their temporal expression pattern or because they were 381 a spliced gene product. 382
This is the first study to our knowledge using RNA-seq to identify the HHV6-B gene 383 expression profile in whole blood collected during periods of HHV-6B reactivation. Previous 384 reports have characterized the expression pattern of several HHV-6B transcripts following 385 experimental in vitro infection of different T cell lines with HHV-6B, 26 and one study described 386 the HHV-6B transcriptome in tumor tissue samples from two patients with DLBCL, 19 although 387 the pathogenic role of HHV-6B in this context is unclear. RNA-seq for transcriptome analysis 388 provides an unbiased approach to identify consistently and highly expressed genes that may 389 increase the sensitivity of targeted RT-qPCR assays for HHV-6B replication in biologic samples. 390
Given that total mRNA isolation from PBMCs in blood samples may be limited by low yields, 391 degradation, coagulation, and the fact that cell purification procedures can skew transcriptome 392 analysis by inducing gene transcription, 29 we chose to perform direct mRNA isolation from 393 whole blood samples using PAXgene tubes to allow for immediate and long-term stabilization of 394 intracellular RNA. 29 395
We demonstrated a broad range of viral gene expression across the HHV-6B genome in 396 whole blood from subjects with concurrent plasma viremia, indicative of lytic replication. We did 397 not detect any HHV-6B transcripts in subjects without concurrent plasma viremia. The 398 previously reported study of two DLBCL tumor samples with HHV-6B infection demonstrated 399 higher RNA-seq read counts mapping to the HHV-6B genome with broader gene expression 400 profiles including almost all known HHV-6B genes. 19 Hierarchical cluster analysis of the HHV-6B 401 transcriptome from whole blood versus DLBCL tumor samples with HHV-6B infection showed 402 similarities but also differences in gene expression profiles that may be explained in part by 403 differences in infected cell types. Nonetheless, we identified five gene transcripts that were represented among the top ten most highly expressed HHV-6B transcripts in all in vivo and in 405 vitro samples (Table 4) . 406
HHV-6B U38 was the only gene transcript detected in all the RNA-seq data sets and 407 was the only viral transcript detectable in two of the whole blood samples. Interestingly, HHV-6B 408 U38 appears to be an immunodominant epitope recognized by human CD4+ T cells. 30 We 409 developed a targeted RT-qPCR assay for U38, which was positive in all tested whole blood 410 samples from patients with HHV-6 viremia, demonstrating the potential utility of this assay for 411 identifying HHV-6B replication in clinical samples. Although U38 is not a spliced gene product 412 leading to the possibility of contamination with genomic DNA, we demonstrated minimal 413 contamination after treatment with DNase. Whereas prior studies have tested the sensitivity and 414 specificity of assays targeting HHV-6B transcripts such as U12, U16/17, U60/66, U79/U80, 415 U89/90, and U100, 11-17 U79 was the only one of these transcripts shared across sample types 416 at a relatively high abundance. Our data also demonstrated potential unique spliceoforms for 417 U79 and U100, which may further compromise the sensitivity of PCR assays for these targets. 418
We also used the RNA-seq data from whole blood to study whether unique host gene 419 expression or cytokine profiles could be demonstrated among patients with and without HHV-6 420 reactivation post-HCT. Provocative data using microarrays demonstrated a unique host gene 421 expression profile in children with primary HHV-6B infection, 31 and other studies have shown 422 associations between specific cytokine levels and HHV-6 infection after HCT. 32 However, we did 423 not find any significant differences in whole blood host gene expression and cytokine profiles 424 between subjects with and without HHV-6 reactivation in this study. However, our sample size 425 was small, no subjects in our cohort had severe HHV-6 infection with end-organ disease, and 426 biologic changes early after HCT (e.g. donor cell engraftment, graft-versus-host disease) likely 427 had larger effects on host gene expression. 428
Strengths of this study included the use of RNA-seq analyses of unique biologic samples 429 to characterize in vivo HHV-6B gene expression and comparison of these findings with in vitro 430 HHV-6B gene expression. Furthermore, we used these data to generate an evidence-based 431 RT-qPCR assay to identify HHV-6B replication in biologic samples. The low overall number of 432 HHV-6B gene transcript reads prevented us from accurately determining the relative abundance 433 of each transcript. Nonetheless, our characterization of the HHV-6B transcriptome in HCT 434 patients with HHV-6B reactivation provides a comprehensive list of viral proteins of biological 435
interest. Future studies using sequentially collected samples from subjects before and after 436 HHV-6B reactivation, as well as in subjects with iciHHV-6, will be important to refine these 437
findings. 438
In conclusion, we demonstrated that RNA-seq can be used to determine HHV-6B gene 439 expression after allogeneic HCT, and these analyses identified the HHV-6B U38 mRNA 440 574 We performed hierarchical clustering analysis to compare the normalized read numbers mapped to each HHV-575 6B gene for whole blood and tumor tissue samples. Data are presented in units of copies/mL. c This subject also had HHV-6B DNA detected on day 32 (+6) with a viral load of 364 copies/mL. Bolded genes are those that were in the top ten most highly expressed transcripts for all sample types. We only used one SupT1 CD4+ T cell culture. The temporal pattern of expression is defined as previously described. 33 a The data sets obtained from cases 1 and 3 were omitted due to a low number of reads to only one transcript (U38). b Normalized read counts expressed in VPMM were averaged between samples. 587 588 There was insufficient RNA isolated to allow for RNA-seq. 590 591
